NASDAQ · MDCXHealthcarePharmaceuticals

Medicus Pharma news

$0.1566+2.96%

Close Sep 29, 2026 · split-adjusted

Articles · 30 days0English, de-duplicated

Positive0

Neutral0

Negative0

About Medicus Pharma

Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis

GlobeNewswire Inc.Jul 31, 7:30 AM ET▲ Positive

The company received regulatory authorization to proceed with a novel precision medicine clinical study, representing a significant regulatory milestone. The study design is innovative and addresses an unmet medical need affecting millions of women. This approval validates the company's development strategy and advances Teverelix® toward potential commercialization, reducing development risk.

Also mentions MDCX

Articles that tag MDCX but are mainly about other companies.

None recently.

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology